Xencor (XNCR) Operating Leases (2019 - 2026)
Xencor (XNCR) reported Operating Leases of $66.6 million for Q1 2026, down 1.76% year-over-year from $67.8 million in Q1 2025, and up 2.93% quarter-over-quarter from $64.7 million in Q4 2025.
Xencor (XNCR) Operating Leases (2019 - 2026) Analysis & Trends
Xencor (XNCR) has 8 years of Operating Leases data on file, last reported at $66.6 million in Q1 2026.
- Operating Leases for Q1 2026 came in at $66.6 million, down 1.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $66.6 million (down 1.76% YoY), and the FY2025 annual result was $64.7 million, down 0.92% from the prior year.
- Operating Leases advanced to $66.6 million in Q1 2026 per XNCR's latest filing, from $64.7 million in the prior quarter.
- Over five years, Operating Leases peaked at $69.3 million in Q3 2025 and troughed at $22.5 million in Q3 2022.
- A 5-year average of $57.5 million and a median of $64.7 million in 2025 frame the typical range for Operating Leases.
- On a YoY basis, Operating Leases climbed as much as 1156.22% in 2022 and fell as far as 33.88% in 2022.
- A 5-year view of Operating Leases shows it stood at $54.9 million in 2022, then increased by 7.46% to $59.0 million in 2023, then increased by 10.7% to $65.3 million in 2024, then slipped by 0.92% to $64.7 million in 2025, then increased by 2.93% to $66.6 million in 2026.
- Business Quant data shows XNCR's Operating Leases at $66.6 million in Q1 2026, $64.7 million in Q4 2025, and $69.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Xencor | 953.38 Mn | 878.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 66.63 Mn |
| Dec 31, 2025 | 64.74 Mn |
| Sep 30, 2025 | 69.27 Mn |
| Jun 30, 2025 | 67.93 Mn |
| Mar 31, 2025 | 67.82 Mn |
| Dec 31, 2024 | 65.34 Mn |
| Sep 30, 2024 | 66.49 Mn |
| Jun 30, 2024 | 68.42 Mn |
| Mar 31, 2024 | 66.81 Mn |
| Dec 31, 2023 | 59.03 Mn |
| Sep 30, 2023 | 60.76 Mn |
| Jun 30, 2023 | 54.62 Mn |
| Mar 31, 2023 | 54.77 Mn |
| Dec 31, 2022 | 54.93 Mn |
| Sep 30, 2022 | 22.54 Mn |
| Jun 30, 2022 | 33.94 Mn |
| Mar 31, 2022 | 33.96 Mn |
| Dec 31, 2021 | 33.97 Mn |
| Sep 30, 2021 | 34.09 Mn |
| Jun 30, 2021 | 2.70 Mn |